Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Plasma cell 1Gynecologic 1Genitourinary 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Breast Neoplasms 10Melanoma 6Triple Negative Breast Neoplasms 5Squamous Cell Carcinoma of Head and Neck 3Sarcoma 3Ovarian Neoplasms 3Carcinoma, Merkel Cell 3Urinary Bladder Neoplasms 2Stomach Neoplasms 2Esophageal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Carcinoma, Hepatocellular 2Uterine Cervical Neoplasms 1Testicular Neoplasms 1Small Cell Lung Carcinoma 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Osteosarcoma 1Neoplasms, Squamous Cell 1Neoplasms, Plasma Cell 1Neoplasm Metastasis 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Non-Hodgkin 1Lymphoma 1Liver Neoplasms 1Kidney Neoplasms 1Inflammatory Breast Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Chondrosarcoma 1

Interventions

belinostat 2Gemcitabine 2Docetaxel 2resiquimod 1poly ICLC 1durvalumab 1Thalidomide 1Quality of Life 1Pentetic Acid 1Patient Reported Outcome Measures 1Molecular Diagnostic Techniques 1Minocycline 1Immunotherapy 1Imatinib Mesylate 1Heparin 1Fluorouracil 1Filgrastim 1Fentanyl 1Drug Therapy 1Cyclophosphamide 1Cryosurgery 1Cisplatin 1Biological Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Chondrosarcoma × poly ICLC × Breast × Clear all
NCT00948961 2016-06-27

A Study of CDX-1401 in Patients With Malignancies Known to Express NY-ESO-1

Celldex Therapeutics

Phase 1/2 Completed
70 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicPlasma cellSarcomaThoracic

Adenocarcinoma, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Chondrosarcoma, Esophageal Neoplasms, Melanoma, Ovarian Neoplasms, Sarcoma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡